Prostate adenocarcinoma · line 1 · ADT + darolutamide + docetaxel (ARASENS triplet)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-ADT-DAROLUTAMIDE-DOCETAXEL`

ID	`IND-PROSTATE-MHSPC-1L-TRIPLET`
Type	Indication
Status	status not declared
Diseases	`DIS-PROSTATE`
Sources	`SRC-ESMO-PROSTATE-2024` `SRC-NCCN-PROSTATE-2025`

Notes

ARASENS (darolutamide + docetaxel + ADT): OS benefit in high-volume mHSPC. Requires docetaxel-eligible patient. Alternative formulations: ADT + abiraterone + docetaxel (PEACE-1) for centers without darolutamide access.

Used By

Algorithms

ALGO-PROSTATE-MHSPC-1L - ALGO-PROSTATE-MHSPC-1L

Handbook Chapters

HB-PROSTATE-MCRPC-1L - Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning